LEUKEMIA, MYELOID, ACUTE

This study is testing a new two-drug combination for adults with acute myeloid leukemia (AML) that has returned or not responded to up to two prior treatments. The goal is to find a safe and effective dose of an experimental drug (DFP-10917) given by IV infusion alongside an exis…

This early-stage study is testing a new drug called JNJ-89853413 for adults with acute myeloid leukemia or myelodysplastic neoplasms that have returned or stopped responding to previous treatments. The main goals are to find a safe dose and see how the body processes the drug. Re…

This is the first study in humans to test a new drug called JNJ-90189892. It aims to find a safe and effective dose for adults whose acute myeloid leukemia or myelodysplastic syndrome has returned or not responded to prior treatments. The study will first determine the safest dos…

This study is testing a new cell therapy called Orca-T for adults with acute myeloid leukemia or myelodysplastic syndrome who need a stem cell transplant but are too frail for the strongest chemotherapy. The therapy uses specially prepared donor cells to help rebuild the patient'…

This early-stage trial is testing a new cell therapy for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to standard treatments. Doctors will collect a patient's own immune cells (T cells), genetically modify them in a lab to better …

This study is testing whether adding a new drug called bleximenib to a standard two-drug treatment works better for older adults with a specific type of acute myeloid leukemia (AML) who are too frail for intensive chemotherapy. It will involve about 600 participants and compare t…

This study is testing whether a combination of two drugs, azacitidine and chidamide, can help keep high-risk acute myeloid leukemia (AML) from coming back after a patient has received a stem cell transplant from a donor. The main goals are to see if this maintenance therapy is sa…

This study is testing if adding an experimental drug called cusatuzumab to a standard two-drug treatment helps people with newly diagnosed acute myeloid leukemia (AML) live longer. It is for adults who are not healthy enough for strong chemotherapy. About 120 participants will be…

This is the first time researchers are giving a new oral drug called BH-30236 to people. The study aims to find a safe dose and see if the drug can help control two aggressive blood cancers—acute myeloid leukemia or myelodysplastic syndrome—that have come back or haven't responde…

This study is testing a new oral drug called enzomenib for people with advanced blood cancers like acute leukemia that have come back or not responded to other treatments. The main goals are to find a safe and effective dose and to see if the drug, given alone or with standard ch…

This study is testing whether adding a drug called chidamide to a standard two-drug treatment is safe and more effective for adults whose acute myeloid leukemia has come back or hasn't responded to prior therapy. The goal is to see if this three-drug combination can help more pat…

This early-stage trial is testing whether adding an experimental drug called ziftomenib to standard leukemia treatments is safe and tolerable for patients. It focuses on adults with acute myeloid leukemia (AML) that has returned or not responded to prior therapy and has specific …

This study aims to understand how a person's genetic makeup influences the side effects they experience and how well they respond to a standard two-drug treatment for acute myeloid leukemia (AML). Researchers will enroll 50 adults newly diagnosed with AML who are receiving azacit…